San Francisco startup Framework Therapeutics is likewise engaged on an oral, when-every day GLP-1 drug named GSBR-1290—the drug surpassed Wall Road’s expectations in June whenever a mid-phase research showed ordinary weight loss of all over 6% and it ideas to begin Yet another mid-stage trial toward the end of the yr—that founder and CEO Raym